Q-omics provides the consensus-scored MIR663AHG profile across patient tissues and cancer cell-line models. MIR663AHG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, MIR663AHG is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, MIR663AHG RNA expression shows 8,530 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight THCA, LUSC, and PAAD as cancer lineages where MIR663AHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR663AHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR663AHG survival associations across molecular data types. MIR663AHG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR663AHG RNA expression–survival associations across cancer types. High MIR663AHG expression shows unfavorable associations in THCA, LUSC, KIRC and LIHC, but favorable associations in LUAD and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for MIR663AHG RNA expression.
This table summarizes MIR663AHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR663AHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR663AHG shows lower tumor expression in LUSC, THCA and LUAD and higher tumor expression in HNSC, UCEC and STAD. The LUSC box plot shows higher MIR663AHG RNA expression in normal versus tumor tissue (log2 FC = −0.420, t-test p < 0.001).
This table shows molecular features associated with MIR663AHG in patient tissues and cancer cell lines. In patient samples, MIR663AHG shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set.
